Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01325688
Registration number
NCT01325688
Ethics application status
Date submitted
25/03/2011
Date registered
30/03/2011
Date last updated
26/02/2016
Titles & IDs
Public title
PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities
Query!
Scientific title
A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities
Query!
Secondary ID [1]
0
0
PEP005-037
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Superficial Basal Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - PEP005 (ingenol mebutate) Gel, 0.05%
Treatment: Devices - Aluminium disk
Treatment: Devices - OpSite(TM) disk
Experimental: Group 1 - PEP005 0.05% gel applied and occluded with an aluminium disk for up to three consecutive days
Experimental: Group 2 - PEP005 0.05% Gel applied and occluded with an OpSite(TM) disk up to three consecutive days
Experimental: Group 3 - PEP005 0.05% applied with no occlusion for up to three consecutive days
Treatment: Drugs: PEP005 (ingenol mebutate) Gel, 0.05%
PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
Treatment: Devices: Aluminium disk
Treatment: Devices: OpSite(TM) disk
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Treatment related Adverse Events, Local Skin Responses; Pigmentation and scarring
Query!
Assessment method [1]
0
0
Number of participants with treatment related Adverse Events, change from baseline in LSR and pigmentation and scarring.
Query!
Timepoint [1]
0
0
120 days
Query!
Secondary outcome [1]
0
0
Histological and clinical clearance of sBCC lesions.
Query!
Assessment method [1]
0
0
Number of participants with histological and clinical clearance of sBCC lesions.
Query!
Timepoint [1]
0
0
120 days
Query!
Eligibility
Key inclusion criteria
- Must be male or female and at least 18 years of age
- Female patients must be of: non-childbearing potential or if of childbearing potential
then have a negative serum and urine pregnancy test and using effective contraception
- Ability to provide informed consent
- primary diagnosed and histologically confirmed sBCC located on the trunk or
extremities which is suitable for excision
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- location of the sBCC lesion within 10cm of an incompletely healed wound, on the hand
or foot, on the breast of women, on the anogenital area.
- Undergone cosmetic or therapeutic procedures within 2cm of the selected treatment area
in the 2 weeks prior to the screening visit.
- Use of acid-containing therapeutic products within 2 cm of the selected treatment area
in the 2 weeks prior to the screening visit
- Use of topical moisturisers/creams/lotions (non-medicated/non-irritant salves are
acceptable), artificial tanners or topical steroids: within 2 cm of the selected
treatment area.
- Have received treatment with immunomodulators, or interferon/interferon inducers,
systematic medications that suppress the immune system or UVB in the last 4 weeks
- Have undergone treatment with 5-FU, imiquimod, diclofenac or photodynamic therapy
within 2 cm of the selected treatment area within 8 weeks prior to any screening
visit.
- Use of systemic retinoids.
- Those who are currently participating in any other clinical trial
- Those known or suspected of not being able to comply with the requirements of the
protocol
- Females who are pregnant or are breastfeeding
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
75
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Southderm Pty Ltd - Kogarah
Query!
Recruitment hospital [2]
0
0
St George Dermatology - Kogarah
Query!
Recruitment hospital [3]
0
0
The Skin Centre - Benowa
Query!
Recruitment hospital [4]
0
0
Specialist Connect - Woolloongabba
Query!
Recruitment hospital [5]
0
0
Dermatology Institute of Victoria - South Yarra
Query!
Recruitment hospital [6]
0
0
St John of God Dermatology - Subiaco
Query!
Recruitment hospital [7]
0
0
Burswood Dermatology - Victoria Park
Query!
Recruitment postcode(s) [1]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [2]
0
0
4217 - Benowa
Query!
Recruitment postcode(s) [3]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [4]
0
0
3141 - South Yarra
Query!
Recruitment postcode(s) [5]
0
0
6008 - Subiaco
Query!
Recruitment postcode(s) [6]
0
0
6100 - Victoria Park
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Peplin
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is primarily designed to investigate whether treatment, once daily for up to three
consecutive days, with PEP005 (ingenol mebutate) Gel, 0.05% will be safe and tolerable in
patients with superficial Basal Cell Carcinoma (sBCC) lesions on the trunk and extremities.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01325688
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jacqueline Morley
Query!
Address
0
0
Peplin Operations
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01325688
Download to PDF